New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:09 EDTCCXIChemoCentryx announces Phase I clinical trial for CCX972 in France
ChemoCentryx announced the initiation of a Phase I clinical trial for CCX872, the company's next-generation of orally administered inhibitors targeting the chemokine receptor known as CCR2. The double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CCX872 in 40 healthy adult subjects. ChemoCentryx' CCR2 program also includes CCX140, the Company's lead CCR2 inhibitor, currently in Phase II clinical trials for the treatment of diabetic nephropathy.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
16:31 EDTCCXIChemoCentryx grated FDA orphan-drug designation for CCX168
Subscribe for More Information
November 18, 2014
16:07 EDTCCXIChemoCentryx atypical hemolytic uremic syndrome treatment granted orphan status
Subscribe for More Information
November 17, 2014
08:52 EDTCCXIChemoCentryx reported additional data from CCX168 Phase II clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use